Ipca Laboratories to Consider Q2 FY27 Results on November 5

Ipca Laboratories Ltd will consider its unaudited Q2 and H1 FY27 financial results on November 5, 2026, following Q1 FY27 consolidated revenue growth of 21% year-on-year to ₹2,788 crore. The meeting is important because management had raised its FY27 revenue-growth guidance to 14-16% after the first-quarter performance.

When will Ipca Labs announce Q2 FY27 results?

Ipca Labs has scheduled a board meeting for November 5, 2026, to approve unaudited financial results for the quarter and half year ended September 2026. The company has identified the date as its upcoming earnings date, while Q1 FY27 results were announced on August 13, 2026.

The Q2 FY27 numbers had not been announced in the information available before the board meeting. As a result, no reported Q2 revenue, profit, margin, or segment figure should be treated as confirmed before the company releases the results. The board meeting will provide the first official update on the September-quarter performance.

Ipca Labs has also kept its insider trading window closed until two days after the declaration of results. This is a standard compliance step intended to restrict trading by designated persons while unpublished price-sensitive information is being considered and subsequently disclosed.

What did Ipca Labs report in Q1 FY27?

Ipca Labs reported consolidated revenue of ₹2,788 crore for Q1 FY27, compared with ₹2,309 crore in Q1 FY26, representing year-on-year growth of 21%. The company reported consolidated EBITDA of ₹630.8 crore, while EBITDA margin improved to 22.88% from 18.39% a year earlier.

Its domestic formulations revenue increased 13% year-on-year to ₹1,082 crore from ₹961 crore. Export revenue rose 34% to ₹603 crore, supported by branded, institutional and generic business. Institutional export revenue grew 107% to ₹119.75 crore, while generic exports increased 27% to ₹340.02 crore.

The API business also contributed to first-quarter growth. Total API revenue was ₹423.72 crore, up 30% year-on-year. Domestic API sales stood at ₹91.37 crore, up 20%, and export API sales were ₹332.35 crore, up 33%.

Which business segments supported Ipca Labs' growth?

Formulations and APIs both supported Ipca Labs' Q1 FY27 growth. Total formulations revenue rose 19% year-on-year to ₹1,685.16 crore, with domestic formulations and export markets contributing to the increase.

Revenue from India was ₹1,229.21 crore in Q1 FY27, compared with ₹1,083.17 crore in the corresponding quarter of FY26. Revenue from outside India was ₹1,558.89 crore, compared with ₹1,225.68 crore a year earlier. The data shows that international operations represented a larger revenue contribution than India during the reported quarter.

Management has said it is focusing on margin improvement and volume-led growth in domestic and US markets. Ajit Kumar Jain, Managing Director and CFO, revised FY27 consolidated revenue-growth guidance to 14-16% from an earlier 12-13%. He also raised EBITDA margin guidance to around 23% from 22%, citing operational efficiency and cost control.

How does Q1 performance compare with Ipca Labs' earlier results?

Ipca Labs entered the Q2 FY27 result period after reporting improved margins in both Q1 FY27 and the comparable Q2 FY26 period. In Q2 FY26, consolidated net total income was ₹2,584.36 crore, up 9% year-on-year, and EBITDA margin was 21.68%, compared with 19.10% in Q2 FY25.

The company reported Q2 FY26 net profit of ₹282.57 crore after exceptional items, up 23% year-on-year. Export income was ₹813.65 crore, up 7%, while Indian formulations income was ₹1,018.90 crore, up 8%. These historical figures provide a comparison point for investors assessing the November 5 disclosure.

For FY26, Ipca Labs reported consolidated revenue growth of 8% to ₹9,646 crore. The company therefore begins FY27 with a higher management revenue-growth target than the growth delivered during FY26, with the Q1 outcome showing stronger momentum in exports and APIs.

Why do the Q2 results matter for investors?

The Q2 result will show whether the Q1 improvement in revenue growth and EBITDA margin continued into the September quarter. Investors will be able to compare the announced figures with management's FY27 guidance of 14-16% revenue growth and an EBITDA margin of around 23%.

The disclosures will also provide an updated view of the domestic formulations, export formulations and API businesses. Q1 performance showed growth across these operations, but the information available before the board meeting does not establish Q2 segment trends. The official results and any related management commentary will be the relevant basis for assessing progress.

The closed trading window remains relevant for market participants because it confirms that the company is in a results-sensitive period. The window will reopen two days after the results declaration, according to the stated arrangement.

Conclusion

Ipca Labs will place Q2 and H1 FY27 unaudited results before its board on November 5, after Q1 consolidated revenue rose 21% to ₹2,788 crore and EBITDA margin reached 22.88%. The first-quarter figures reflected contributions from domestic formulations, exports and APIs, while management raised its full-year growth and margin guidance.

The next material update is the company’s official November 5 results disclosure. Investors will watch the reported Q2 revenue, margins, segment performance and any management comments on the 14-16% FY27 revenue-growth target and EBITDA margin guidance of around 23%.